{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:58:58Z","timestamp":1785347938900,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,29]]},"DOI":"10.7759\/cureus.113606","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:05:35Z","timestamp":1785344735000},"source":"Crossref","is-referenced-by-count":0,"title":["BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase"],"prefix":"10.7759","author":[{"given":"Valeria","family":"Gonz\u00e1lez Quiroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Sergio","family":"Campillo Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Garay Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe de los Angeles","family":"Salazar Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Fabian","family":"Vallejo Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic myeloid leukemia in 2020","volume":"4","author":"Hehlmann R","year":"2020","unstructured":"Hehlmann R. Chronic myeloid leukemia in 2020. Hemasphere. 2020, 4:e468. 10.1097\/HS9.0000000000000468","journal-title":"Hemasphere"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger MW","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000, 96:3343-56.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2023.9","article-title":"Targeting BCR-ABL1-positive leukaemias: a review article","volume":"1","author":"Leak S","year":"2023","unstructured":"Leak S, Horne GA, Copland M. Targeting BCR-ABL1-positive leukaemias: a review article. Camb Prism Precis Med. 2023, 1:e21. 10.1017\/pcm.2023.9","journal-title":"Camb Prism Precis Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma D","year":"2009","unstructured":"Verma D, Kantarjian HM, Jones D, et al.. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009, 114:2232-5. 10.1182\/blood-2009-02-204693","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01082-4","article-title":"Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets","volume":"35","author":"Adnan-Awad S","year":"2021","unstructured":"Adnan-Awad S, Kim D, Hohtari H, et al.. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2021, 35:1964-75. 10.1038\/s41375-020-01082-4","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16627","article-title":"Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia","volume":"189","author":"Gong Z","year":"2020","unstructured":"Gong Z, Zhou T, Liu H, et al.. Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. Br J Haematol. 2020, 189:e207-11. 10.1111\/bjh.16627","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-1.14300","article-title":"Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"42","author":"Kearney L","year":"2020","unstructured":"Kearney L, Crampe M, Langabeer SE. Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic myeloid leukemia. Exp Oncol. 2020, 42:78-9. 10.32471\/exp-oncology.2312-8852.vol-42-no-1.14300","journal-title":"Exp Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley JF","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NC, et al.. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025, 39:1797-813. 10.1038\/s41375-025-02664-w","journal-title":"Leukemia"},{"key":"ref10","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic myeloid leukemia. (2025). Accessed: July 17, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1427."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil E","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016, 374:2209-21. 10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross NC","year":"2015","unstructured":"Cross NC, White HE, Colomer D, et al.. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015, 29:999-1003. 10.1038\/leu.2015.29","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.783.783","article-title":"Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients - a follow-up analysis of the German CML study IV","volume":"118","author":"Hanfstein B","year":"2011","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, et al.. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients - a follow-up analysis of the German CML study IV. Blood. 2011, 118:783. 10.1182\/blood.V118.21.783.783","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani M","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al.. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013, 122:872-84. 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger L","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, D\u00f6hner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017, 35:934-46. 10.1200\/JCO.2016.71.2208","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188812","article-title":"Unveiling cryptic BCR-ABL1 rearrangements: diagnostic challenges and clinical impact in myeloid malignancies","volume":"26","author":"Ferrari A","year":"2025","unstructured":"Ferrari A, Salvesi C, Fonzi E, et al.. Unveiling cryptic BCR-ABL1 rearrangements: diagnostic challenges and clinical impact in myeloid malignancies. Int J Mol Sci. 2025, 26:8812. 10.3390\/ijms26188812","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2324-0","article-title":"Management of chronic myeloid leukemia in blast crisis","volume":"94 Suppl 2","author":"Sau\u00dfele S","year":"2015","unstructured":"Sau\u00dfele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015, 94 Suppl 2:S159-65. 10.1007\/s00277-015-2324-0","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516056-bcrabl1-e1a2-p190-positive-myeloid-blast-neoplasm-diagnostic-challenges-in-distinguishing-de-novo-acute-myeloid-leukemia-from-previously-unrecognized-chronic-myeloid-leukemia-in-the-blast-phase","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:05:36Z","timestamp":1785344736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516056-bcrabl1-e1a2-p190-positive-myeloid-blast-neoplasm-diagnostic-challenges-in-distinguishing-de-novo-acute-myeloid-leukemia-from-previously-unrecognized-chronic-myeloid-leukemia-in-the-blast-phase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.113606","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}